1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

  • October 2017
  • 202 pages
  • ID: 4141093
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Summary
Diabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both (ADA, 2014b). Insulin is a hormone that contributes to the regulation of blood glucose levels by stimulating the uptake of glucose by cells for energy. Consequently, insufficient insulin activity results in chronic hyperglycemia, which is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels.

Market for type 2 diabetes mellitus (T2DM) is expected to grow from $1.92 billion in 2016 to $2.96 billion in 2023, at a compound annual growth rate (CAGR) of 6.3%. This growth will be driven by the rapidly expanding prevalence population, due to increasingly aging populations and sedentary lifestyles, as well as an increase in diagnosis and treatment rates, due to rising disease awareness among the public. The increased uptake of recently approved and emerging branded therapeutics, in favor of lower-cost generic products, will also propel market growth.

Pipeline for T2DM is large, with 609 products at a disclosed stage of development, although the majority of these drugs are at an early stage. About 52% of the pipeline is in the Preclinical stage, while 17% is in the Discovery stage. Though 28% of the pipeline is in clinical development, only 2% is in the Pre-registration stage. The late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes compared with currently marketed products. By 2023, Novo Nordisk’s OG-217SC (oral semaglutide) is expected to be in the market.

The top-selling drugs presently - Januvia, Victoza, Novolog, and Invokana - are expected to remain dominant within the disease cluster and are all - along with many other top-selling products - indicated for T2DM. However, three of the anticipated top 10 best-selling drugs of 2023 will be new to the South-East Asia market.

The report “Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth” covers epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications of type 2 diabetes mellitus (T2DM),

In depth, this report provides the following -
- Provides an overview of the T2DM marketed products landscape, including product profiles of key marketed products and heatmaps that compare the safety and efficacy parameters of the various drugs.
- Analyzes the T2DM pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
- Provides detailed analysis of recent clinical trials in T2DM by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Supplies forecasts for the T2DM market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2016-2023 period. The eight South-East Asia markets are covered and data are presented at a country level.
- Provides detailed analysis of key market drivers and barriers for T2DM in South-East Asia markets.
- Describes the major deals that have taken place in the global T2DM market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value. Licensing and co-development deals by region are also included.

Companies mentioned in this report: Pfizer, Theracos, Merck & Co., Sanofi.

Scope
The current T2DM market in South-East Asia contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
There are over 609 active pipeline molecules, with most of the late-stage investigational drug candidates featuring improved dosing regimens and administration routes compared with currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- Is there potential for pipeline molecules to address unmet needs within the T2DM market?
Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 62.1%, with the overall attrition rate for T2DM standing at 88.3%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2016-2023 forecast period, the T2DM therapeutics market in South-East Asia is expected to increase in value at a CAGR of 6.3%, from $1.92 billion to over $2.96 billion.
- Which markets make the most significant contribution to the regional market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy
- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed product landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
- Discover trends in licensing and co-development deals concerning T2DM products, and identify the major strategic consolidations that have shaped the commercial landscape.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($4995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2019

Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • August 2019

Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, "Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2019", ...

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019" provides an ...

Diabetic Gastroparesis - Pipeline Review, H2 2019

Diabetic Gastroparesis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Diabetic Gastroparesis - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2019, provides an overview of the Diabetic Gastroparesis ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on